Which has stronger valuation and earnings, SION or CTOR?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is SION or CTOR more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Citius Oncology N/A -102.98% -43.49%

Does the media refer more to SION or CTOR?

In the previous week, Sionna Therapeutics had 4 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Sionna Therapeutics and 2 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.88 beat Sionna Therapeutics' score of 0.23 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTOR or FATE?

In the previous week, Fate Therapeutics had 2 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Citius Oncology. Fate Therapeutics' average media sentiment score of 1.04 beat Citius Oncology's score of 0.88 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CTOR or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A

Is CTOR or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Galectin Therapeutics N/A N/A -176.83%

Does the media prefer CTOR or ANIK?

In the previous week, Anika Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Citius Oncology. Anika Therapeutics' average media sentiment score of 1.73 beat Citius Oncology's score of 0.88 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is ACIU or CTOR more profitable?

Citius Oncology has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. AC Immune's return on equity of -100.17% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% Citius Oncology N/A -102.98% -43.49%

Does the media refer more to ACIU or CTOR?

In the previous week, AC Immune and AC Immune both had 2 articles in the media. AC Immune's average media sentiment score of 1.25 beat Citius Oncology's score of 0.88 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Citius Oncology (CTOR) Competitors

$0.79 +0.01 (+1.86%)

As of 09/3/2026 03:59 PM Eastern

Compare

CTOR vs. SION, FATE, GALT, ANIK, and ACIU

Should you buy Citius Oncology stock or one of its competitors? Citius Oncology's main competitors and comparable companies include Sionna Therapeutics (SION), Fate Therapeutics (FATE), Galectin Therapeutics (GALT), Anika Therapeutics (ANIK), and AC Immune (ACIU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Citius Oncology compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

70.5% of Citius Oncology shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sionna Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market.

Sionna Therapeutics presently has a consensus price target of $42.22, suggesting a potential upside of 525.51%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 657.38%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Citius Oncology is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sionna Therapeutics' return on equity of -32.94% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Citius Oncology	N/A	-102.98%	-43.49%

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

In the previous week, Sionna Therapeutics had 4 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Sionna Therapeutics and 2 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.88 beat Sionna Therapeutics' score of 0.23 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Citius Oncology beats Sionna Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Citius Oncology compare to Fate Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Citius Oncology has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Fate Therapeutics	$6.65M	43.60	-$136.32M	-$1.05	N/A

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 657.38%. Fate Therapeutics has a consensus price target of $5.90, indicating a potential upside of 143.80%. Given Citius Oncology's higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Citius Oncology has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

In the previous week, Fate Therapeutics had 2 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Citius Oncology. Fate Therapeutics' average media sentiment score of 1.04 beat Citius Oncology's score of 0.88 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Citius Oncology has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

Summary

Fate Therapeutics beats Citius Oncology on 8 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to Galectin Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Citius Oncology has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 657.38%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 152.87%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Citius Oncology is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Galectin Therapeutics	N/A	N/A	-176.83%

In the previous week, Citius Oncology had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Citius Oncology and 0 mentions for Galectin Therapeutics. Citius Oncology's average media sentiment score of 0.88 beat Galectin Therapeutics' score of 0.30 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Positive
Galectin Therapeutics	Neutral

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Summary

Citius Oncology beats Galectin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Citius Oncology compare to Anika Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 657.38%. Anika Therapeutics has a consensus target price of $21.00, indicating a potential upside of 0.00%. Given Citius Oncology's higher probable upside, research analysts plainly believe Citius Oncology is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Citius Oncology has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Anika Therapeutics	-3.14%	0.20%	0.15%

In the previous week, Anika Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Citius Oncology. Anika Therapeutics' average media sentiment score of 1.73 beat Citius Oncology's score of 0.88 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Citius Oncology has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Anika Therapeutics has higher revenue and earnings than Citius Oncology. Anika Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Anika Therapeutics	$112.82M	2.49	-$10.88M	-$0.27	N/A

Summary

Anika Therapeutics beats Citius Oncology on 11 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

AC Immune has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, indicating that its stock price is 252% more volatile than the broader market.

In the previous week, AC Immune and AC Immune both had 2 articles in the media. AC Immune's average media sentiment score of 1.25 beat Citius Oncology's score of 0.88 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Citius Oncology has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. AC Immune's return on equity of -100.17% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Citius Oncology	N/A	-102.98%	-43.49%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 9.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Citius Oncology has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	69.18	-$85.03M	-$0.54	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 155.97%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 657.38%. Given Citius Oncology's higher possible upside, analysts clearly believe Citius Oncology is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Citius Oncology beats AC Immune on 8 of the 14 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.31M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.69	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.84	16.29	12.89	6.14
Net Income	-$24.76M	-$22.72M	$3.47B	$349.01M
7 Day Performance	2.14%	0.34%	0.61%	-0.27%
1 Month Performance	20.03%	8.52%	5.73%	0.68%
1 Year Performance	-57.64%	52.66%	25.37%	14.84%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	2.0789 of 5 stars	$0.79 +1.9%	$6.00 +657.4%	-59.8%	$72.31M	N/A	N/A	N/A	News Coverage Analyst Downgrade Gap Up
SION Sionna Therapeutics	2.7358 of 5 stars	$6.43 -0.5%	$42.22 +556.8%	-72.5%	$289.81M	N/A	N/A	35
FATE Fate Therapeutics	3.2146 of 5 stars	$2.41 -1.0%	$5.90 +145.3%	+142.0%	$286.97M	$6.65M	N/A	550	News Coverage Positive News
GALT Galectin Therapeutics	1.7271 of 5 stars	$4.34 +4.1%	$11.00 +153.5%	-3.1%	$285.83M	N/A	N/A	9
ANIK Anika Therapeutics	3.1176 of 5 stars	$21.19 +0.4%	$21.00 -0.9%	+133.1%	$284.19M	$112.82M	N/A	300	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. SION, FATE, GALT, ANIK, and ACIU

How does Citius Oncology compare to Sionna Therapeutics?

Summary

How does Citius Oncology compare to Fate Therapeutics?

Summary

How does Citius Oncology compare to Galectin Therapeutics?

Summary

How does Citius Oncology compare to Anika Therapeutics?

Summary

How does Citius Oncology compare to AC Immune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. SION, FATE, GALT, ANIK, and ACIU

How does Citius Oncology compare to Sionna Therapeutics?

Do institutionals & insiders hold more shares of SION or CTOR?

Which has more risk and volatility, SION or CTOR?

Do analysts recommend SION or CTOR?

Is SION or CTOR more profitable?

Which has stronger valuation and earnings, SION or CTOR?

Does the media refer more to SION or CTOR?

Summary

How does Citius Oncology compare to Fate Therapeutics?

Which has better valuation & earnings, CTOR or FATE?

Do analysts recommend CTOR or FATE?

Is CTOR or FATE more profitable?

Does the media favor CTOR or FATE?

Do institutionals & insiders have more ownership in CTOR or FATE?

Which has more volatility & risk, CTOR or FATE?

Summary

How does Citius Oncology compare to Galectin Therapeutics?

Do institutionals and insiders hold more shares of CTOR or GALT?

Which has more risk & volatility, CTOR or GALT?

Do analysts rate CTOR or GALT?

Is CTOR or GALT more profitable?

Does the media favor CTOR or GALT?

Which has stronger valuation & earnings, CTOR or GALT?

Summary

How does Citius Oncology compare to Anika Therapeutics?

Do institutionals and insiders believe in CTOR or ANIK?

Do analysts prefer CTOR or ANIK?

Is CTOR or ANIK more profitable?

Does the media prefer CTOR or ANIK?

Which has more risk and volatility, CTOR or ANIK?

Which has stronger earnings and valuation, CTOR or ANIK?

Summary

How does Citius Oncology compare to AC Immune?

Which has more risk & volatility, ACIU or CTOR?

Does the media refer more to ACIU or CTOR?

Is ACIU or CTOR more profitable?

Do institutionals & insiders hold more shares of ACIU or CTOR?

Which has preferable valuation and earnings, ACIU or CTOR?

Do analysts prefer ACIU or CTOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools